Palvella Therapeutics PVLA
NASDAQ PVLA
$163.94 -4.77 (-2.83%)
At close: Nov 11, 2026 · 4:00 PM EST

Palvella Therapeutics (PVLA) Gains from Sales and Divestitures (2017 - 2024)

Updated

Palvella Therapeutics' Gains from Sales and Divestitures came in at -$63,625 for Q3 2017.

Analysis

Palvella Therapeutics (PVLA) Gains from Sales and Divestitures (2017 - 2024) Analysis & Trends

For FY2016, Palvella Therapeutics' Gains from Sales and Divestitures was -$49,437.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Palvella Therapeutics 2.47 Bn 2.23 Bn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 -6,000.00
Sep 30, 2017 -63,625.00
API Access

Palvella Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=PVLA&period=max&api_key=YOUR_API_KEY